Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis

With an estimated number of deaths of almost 1.8 million in 2020, lung cancer is the most common cause of cancer-related death worldwide [1]. Of these, up to 85% are non-small cell lung cancers (NSCLCs), a disease entity which encompasses distinct mutational and histological subtypes, [2]. Given the extremely poor survival rates of advanced and metastatic NSCLC, increasing efforts have been made to design screening programs for high-risk populations (e.g. heavy smokers). Therefore, other than a mortality benefit [3], it is expected that the prevalence of early-stage NSCLC (ES-NSCLC) will increase in the upcoming years.

Source: Cancer Treatment Reviews - September 20, 2022 Category: Cancer & Oncology Authors: Stefania Volpe, Gaia Piperno, Francesca Colombo, Annalisa Biffi, Stefania Comi, Federico Mastroleo, Anna Maria Camarda, Alessia Casbarra, Federica Cattani, Giulia Corrao, Filippo de Marinis, Lorenzo Spaggiari, Matthias Guckenberger, Roberto Orecchia, Dani Source Type: research